Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study | Pfizer

Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second doseVaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined

[dltlt]

BNT162b2 が南アでの接種試験でパーフェクトな結果を出した……と聞いたが、プラセボ区での発症も9名と少なく、そのうち6名がB.1.351であったとしても、即断は難しい結果に見える。